Scholarlink

Background <p>Glutamate dehydrogenase (GDH) levels are known to be important in predicting the development of complications associated with liver disease.</p> Aim <p>In this study, we aimed to investigate the relationship between GDH activity and liver fibrosis grades, APRI, AAR, FIB-4 and AFP levels in patients with viral hepatitis B and hepatocellular carcinoma.</p> Methods <p>The study group consisted of 95 individuals, including 65 HBV and 30 HCC patients, while the control group consisted of 45 healthy volunteers. Routine analyses, FibroScan evaluations, and non-invasive scoring were performed on the participants. GDH levels were determined using an ELISA kit.</p> Results <p>Serum GDH activity was significantly higher in the HBV and HCC groups compared to the control group (<i>p</i> &lt; 0.001). Similarly, AAR, FIB-4, and APRI values showed a progressive increase in parallel with disease progression. In patients with chronic HBV infection, GDH, AAR, FIB-4, and APRI levels increased markedly with advancing fibrosis stages. In HCC cases, these parameters were also significantly elevated in the advanced fibrosis stage (F4) (<i>p</i> &lt; 0.01 and <i>p</i> &lt; 0.001). GDH demonstrated a high diagnostic performance, with an AUC of 0.808 in HCC. Correlation analysis revealed a significant positive association between GDH and AST levels in the HBV group (r = 0.35, <i>p</i> = 0.01). Moreover, FIB-4 and APRI indices showed strong positive correlations with AST, GGT, and LDH levels.</p> Conclusions <p>These findings suggest that GDH, in conjunction with non-invasive fibrosis indices, may serve as a potential biomarker reflecting hepatic injury and fibrosis severity.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Glutamate dehydrogenase activity and non-ınvasive fibrosis ındices (APRI, AAR, FIB-4) compared to FibroScan in chronic hepatitis B and hepatocellular carcinoma

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年4月17日

查看全文
  • Nuray Üremiş,
  • Kadir Gişi,
  • Teoman Şakalar,
  • Fatma İnanç Tolun

摘要

Background

Glutamate dehydrogenase (GDH) levels are known to be important in predicting the development of complications associated with liver disease.

Aim

In this study, we aimed to investigate the relationship between GDH activity and liver fibrosis grades, APRI, AAR, FIB-4 and AFP levels in patients with viral hepatitis B and hepatocellular carcinoma.

Methods

The study group consisted of 95 individuals, including 65 HBV and 30 HCC patients, while the control group consisted of 45 healthy volunteers. Routine analyses, FibroScan evaluations, and non-invasive scoring were performed on the participants. GDH levels were determined using an ELISA kit.

Results

Serum GDH activity was significantly higher in the HBV and HCC groups compared to the control group (p < 0.001). Similarly, AAR, FIB-4, and APRI values showed a progressive increase in parallel with disease progression. In patients with chronic HBV infection, GDH, AAR, FIB-4, and APRI levels increased markedly with advancing fibrosis stages. In HCC cases, these parameters were also significantly elevated in the advanced fibrosis stage (F4) (p < 0.01 and p < 0.001). GDH demonstrated a high diagnostic performance, with an AUC of 0.808 in HCC. Correlation analysis revealed a significant positive association between GDH and AST levels in the HBV group (r = 0.35, p = 0.01). Moreover, FIB-4 and APRI indices showed strong positive correlations with AST, GGT, and LDH levels.

Conclusions

These findings suggest that GDH, in conjunction with non-invasive fibrosis indices, may serve as a potential biomarker reflecting hepatic injury and fibrosis severity.